|
WO2020232063A1
|
|
Synergistic combinations of arginine-producing bacteria and/or ammonia-consuming bacteria and checkpoint inhibitors and methods of use thereof
|
|
WO2020097424A1
|
|
Combination therapies of microorganisms and immune modulators for use in treating cancer
|
|
WO2019232415A1
|
|
Bacteria engineered to treat liver disease
|
|
WO2019090101A1
|
|
Engineered bacteria expressing racemase for treating diseases associated with hyperammonemia
|
|
WO2019014391A1
|
|
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
|
WO2018237198A1
|
|
Bacteria for the treatment of disorders
|
|
CN110913875A
|
|
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
|
CA3013770A1
|
|
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
|
|
CA3011283A1
|
|
Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
|
|
AU2016356684A1
|
|
Bacteria engineered to reduce hyperphenylalaninemia
|
|
US2018312851A1
|
|
Bacteria Engineered to Treat Diseases that Benefit from Reduced Gut Inflammation and/or Tightened Gut Mucosal Barrier
|
|
AU2016346646A1
|
|
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
|
|
AU2016303662A1
|
|
Bacteria engineered to treat disorders involving propionate catabolism
|
|
US2019298779A1
|
|
Bacteria engineered to treat metabolic diseases
|
|
AU2016274311A1
|
|
Bacteria engineered to treat diseases associated with hyperammonemia
|
|
AU2016226234A1
|
|
Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier
|
